Clinical Trial: Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed AML


Intensive chemotherapy is one way of treating acute myeloid leukemia (AML), but many older adults have difficulty tolerating the side effects. Memorial Sloan Kettering hematologist-oncologist Ellin Berman discusses a study that evaluates the safety and effectiveness of the investigational drug sapacitabine in patients age 70 and older who are newly diagnosed with AML.